Alliances

Xencor is collaborating with CSL Ltd. to provide access to Xencor's XmAb® technology platform to enhance the ADCC effector function of its therapeutic antibodies.
Xencor is collaborating with Pfizer using Xencor's Xtend™ half-life prolongation technology and XmAb® ADCC enhancing technology to optimize performance of the company's therapeutic monoclonal antibodies.
Xencor is collaborating with Merck to provide access to Xencor's Xtend™ half-life prolongation technology for the development of antibodies towards an undisclosed Merck drug target.
Xencor is collaborating with MedImmune to create monoclonal antibodies with greatly enhanced potency. MedImmune will use Xencor's XmAb® engineered Fc's to improve antibodies against select MedImmune proprietary cancer targets.
Genentech has exclusively licensed XmAb® technology from Xencor for three targets in cancer and autoimmune disease and is collaborating to develop next generation antibodies against these targets. The targets include CD20 and Her2, which are currently targeted by Genentech's Rituxan® (rituximab) and Herceptin® (trastuzumab), respectively, and a third undisclosed antigen.
Xencor is collaborating with Lilly to use PDA® technology to improve the physical and biological properties of a protein therapeutic. This collaboration leverages Xencor's unique capability to control amino acid sequence for the improvement of complex biophysical traits. Lilly is also licensing Xencor's ImmunoFilter technology to evaluate the potential immunogenicity of its therapeutic proteins.
Xencor is collaborating with Boehringer Ingelheim to create monoclonal antibodies with greatly enhanced potency. Boehringer Ingelheim will use Xencor's XmAb® engineered Fc's to improve antibodies against select Boehringer Ingelheim.
Xencor is collaborating with Human Genome Sciences to humanize a portfolio of monoclonal antibodies and to improve their potency. We are using our proprietary XmAb® Fv and Fc technologies to create antibody candidates against select Human Genome Sciences targets.